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Abstract: Background. Our aim was to evaluate the acceler-
ation of a hyperfractionated, concurrent chemoradiation regimen
(HxCRT) for advanced head and neck squamous cell carcinoma
(HNSCC).
Methods. Patients with unresectable HNSCC were treated
based on a previously published HxCRT regimen: 1.25 Gy twice
daily to 70 Gy concurrent with cisplatin 12 mg/m2/day and
5-fluorouracil 600 mg/m2/day for 5 days, weeks 1, 5. This regimen
was accelerated in this series by shortening the treatment from 7 to
6 weeks by omitting the planned mid-treatment 1-week break.
Results. Forty-six patients with T3-4/N3 disease were treated.
The main acute toxicity was pharyngeal. Median weight change
during therapy in patients with and without enteral feeding tubes
was 3.8% and 7.9%, respectively (p ¼ .08). Fifteen percent
had late grade III pharyngeal toxicity. Local/regional and distant
failure rates were 28% and 17%, respectively; 52% are alive
without evidence of disease.
Conclusions. In nonresectable HNSCC, acceleration of the
HxCRT regimen is feasible, requiring enteral feeding tubes during
therapy in most patients. VC 2006 Wiley Periodicals, Inc. Head
Neck 29: 137–142, 2007
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Locally advanced squamous cell carcinoma of the
head and neck (HNSCC) remains a challenging dis-
ease to treat, with overall survival with current
therapy of 50%.1 Recent approaches to improve
standard treatment have included: adding concur-
rent chemotherapy to radiation,2,3 altered fractio-
nated irradiation,4 and combinations of altered
fractionation and concurrent chemotherapy.1,5,6 In
1998, Brizel et al,1 fromDukeUniversity, published
a randomized study comparing hyperfractionated
chemoradiation (HxCRT) to hyperfractionated radio-
therapy (RT) alone in locally advanced HNSCC.
They demonstrated that the addition of concurrent
chemotherapy to hyperfractionated RT resulted in a
significant advantage in local tumor control and a
borderline significant benefit in overall survival,
comparedwith hyperfractionatedRTalone.
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An important limitation of the intensification
of the treatment regimens is their accompanying
toxicity. Frequent grade III-IV mucositis and sig-
nificant weight loss have become expected toxic-
ities of aggressive regimens.1,5–7 To manage these
toxicities, the Duke University HxCRT protocol
required a 1-week planned treatment break in
mid-therapy. Another strategy that has been used
to reduce treatment-related weight loss and to
prevent hospitalizations and treatment breaks is
prophylactic enteral feeding tubes.8–10
We report in this paper our experience in accel-
erating the HxCRT regimen (AccHxCRT) for pa-
tients with locally advanced HNSCC. The patients
selected for this series had unresectable local/
regional disease that precluded them from other
institutional protocols of organ preservation that
were open at the time (in those protocols, resec-
table disease was an eligibility criterion and in-
duction chemotherapy was used to select patients
for surgery vs. chemoradiation). Acceleration was
achieved by the elimination of the planned 1-week
treatment break in the original HxCRT regimen,
resulting in reduced overall treatment time from
7 to 6 weeks, and prophylactic enteral feeding
tubes were used in an effort to reduce weight loss
during therapy. We expected this regimen modifi-
cation to be beneficial, in view of local/regional tu-
mor control advantages gained by reduced overall
treatment time to a similar extent in randomized
studies of accelerated radiation alone.4,11
MATERIALS AND METHODS
Patients and Therapy. This study was approved
by the institutional review boards of the University
of Michigan and the affiliated Veterans Adminis-
tration Hospital, and all patients underwent de-
tailed informed consent. Eligible patients included
patients without evidence of distant metastatic
disease whose tumors were judged to be nonre-
sectable. Nonresectability criteria included neck
metastases encircling the carotid artery, tumors
involving the prevertebral fascia, and nonnaso-
pharyngeal tumors extending to the base of skull.
In addition, patients in whom surgery would have
required laryngo-glosso-pharyngectomy and patients
with significant nodal involvement of the low neck
whose prognosis was judged to be poor and there-
fore not recommended for extensive surgery were
eligible for this treatment protocol. Radiation was
given in 1.25-Gy fractions twice a day at least
6 hours apart. A total dose of 70 Gy was delivered
to the gross tumor volume over 6 weeks without
any planned treatment breaks. Target volumes at
risk of subclinical disease received 50 to 60 Gy.
Conformal 3-dimensional radiotherapy techni-
ques were used, including beam’s-eye views to
ensure adequate target coverage. The spinal cord
was shielded at 40 Gy. Dose homogeneity was re-
stricted to67% prescribed dose. No specific effort
was made to spare the salivary glands in most of
these patients because of clinic-related con-
straints on lengthy treatment time in patients
receiving twice-daily therapy. Optic nerve doses
were limited to maximum of 54 Gy. No reduced
dose was required for any substantial part of the
gross disease in any of the 8 patients with para-
nasal sinus cancer. Chemotherapy consisted of
5-fluorouracil (5-FU) given as continuous infu-
sion, 600 mg/m2/day, and cisplatin, 12 mg/m2/day,
for 5 days in weeks 1 and 5. Hydration and antie-
metics during chemotherapy were delivered
according to standard clinical care.
All patients received narcotics, mostly starting
in the third week and tapered-off on average at
1 month after completing RT. Prophylactic nysta-
tin was provided routinely, and patients develop-
ing overt fungal infection received fluconazole.
Twice-weekly intravenous fluids were delivered to
patients with >10%weight loss (besides cisplatin-
related hydration). A dedicated team consisted of
a nurse, nutritionist, and physician team during
treatment. Patients with dysphagia more than
3 months after therapy were referred to the Speech
and Swallowing Therapy service for evaluation.
All patients in whom the pharynx was included
in the high-dose treatment volumes (patients with
oropharyngeal, hypopharyngeal, and laryngeal
primaries, or large neck nodes) were referred for
percutaneous endoscopic gastrostomy (PEG) at
the start of treatment in order to improve treat-
ment tolerance. Patients were assessed weekly
and following treatment every 6 to 8 weeks during
the first 2 years and every 3 months thereafter for
acute and late toxicity. Progression was defined
primarily by clinical exam and contrast-enhanced
CTscans performed at 6-month intervals. Toxicity
was scored using the Radiation Therapy and On-
cology Group (RTOG) Acute and Late Radiation
Morbidity Scoring Criteria. In addition, patients
had weekly recording of weight while on treat-
ment.
Survival was calculated from the date of treat-
ment initiation to the date of death or last follow-
up. Survival curves were calculated by the product-
limit (Kaplan-Meier) method. Confidence intervals
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for binomial probabilities were calculated by the
likelihood ratio method. Two-tailed tests are re-
ported. Local-regional failure was reported by cu-
mulative incidence,12 which allows estimation of
incidence rates in the presence of competing risks
from other causes. Statistical calculations were
performed using SAS version 9.1.
RESULTS
Forty-six patients with HNSCC were treated with
AccHxCRT between November 1999 and Decem-
ber 2003. Patient characteristics are displayed in
Table 1. Ninety-one percent of the patients had
American Joint Committee on Cancer (AJCC)
stage IV disease, with the remainder having stage
III disease; all had tumor (T) classification 3-4
except for 1 patient with an unknown primary
and advanced neck disease. Fifty-nine percent had
oropharyngeal cancers, with base of tongue the
most common subsite. Other prominent sites included
paranasal sinuses (13%) and oral cavity (9%).
The treatment course was completed in almost
all patients within 6 weeks. Three patients had
each a treatment break of more than 3 days due to
toxicity or poor compliance. Median delivered RT
dose was 70 Gy. All but 2 patients received 70 Gy,
with the exception of 1 patient who refused the
final treatment and received 67.5 Gy and 1 patient
who received a small-volume boost to total 78.5
Gy. Full dose chemotherapy was received by 36/46
(78%) patients, with the remaining 10 patients
completing only a single cycle or requiring chemo-
therapy dose reductions in the second cycle, due to
severe mucositis/skin desquamation, or due to
patient refusal to receive a second cycle.
Forty-two of 46 (91%) patients had their oral
cavity, oropharynx, or hypopharynx in the high-
dose RT volumes (excluding 4 patients with para-
nasal cancer). Twenty-two (52%) of these patients
had prophylactic PEG placement. The reasons for
nonplacement were patient refusal or need to start
therapy before a PEG could be placed. Of the
patients without prophylactic PEG, 9 received PEG
during treatment and 5 had PEG within 3 weeks
after the completion of treatment for progressive
dysphagia and weight loss.
Severe toxicity data is summarized in Table 2.
Three patients (6.5%) died of treatment-related
(neutropenic sepsis and aspiration pneumonia) or
possible treatment-related (cerebrovascular event
4 months after therapy) causes. Mucositis and dys-
phagia were the most prevalent severe acute toxic-
ities. The median weight change relative to pre-
therapy in all patients was 6.2% (range,32.9%
to +11.2%). The median percentage weight change
in patients without prophylactic feeding tube was
7.9% (range, 32.9% to +7.8%), compared with
median weight change of 3.8% (range, 19.2%
to +11.2%) in patients with prophylactic feeding
tube (p ¼ .08). Moist skin desquamation was ob-
served in six (13%) patients.
Late grade II-III toxicity excluding xerostomia
was observed in 18/46 (39%) patients, and the
Table 1. Patient and tumor characteristics.







Median age (range), y 56 (31–78)
Tumor site
Oropharynx 27










Table 2. Common acute and late severe toxicities.*.
















Skin necrosis requiring surgery 1
Nasal stenosis 1
Hearing loss 1
*Grade V toxicities included 1 each with neutropenic sepsis and aspi-
ration pneumonia, and 1 cerebrovascular event (possibly treatment
related).
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most common was dysphagia. Fourteen patients
required PEG for >3 months for ongoing nutri-
tional support, and 5 patients required PEG sup-
port beyond 6 months, with 1 patient requiring
PEG for 2 years. Strictures requiring dilation
occurred in 7 patients. All were detected during
the workup of dysphagia or aspiration between 2
and 8 months after the completion of therapy. The
workup in all these patients included videofluoro-
scopy and laryngoscopy/esophagoscopy under an-
esthesia. The primary tumor sites in patients with
strictures were posterior pharyngeal wall (3 pa-
tients), oropharynx (3 patients), and hypopharynx
(1 patient). In 6/7 patients, the strictures were
located in the post-cricoid hypopharynx, and in
1 patient in the upper esophagus. The doses deliv-
ered to the sites of strictures were 70 Gy (4 pa-
tients), 60 Gy (1 patient), and 50 Gy (2 patients).
Following dilation of the strictures, 3 patients
continued to depend on tube feeding, 2 patients
ate most of their food but required supplemental
tube feeding, and 2 patients did not require tube
feeding.
At a median follow-up of 31 months (range, 6–
69 months), 17 patients (37%) have had docu-
mented clinical failure, 15 of whom died of disease.
Thirteen patients (28%) experienced local/regional
failure (see Figure 1), 4 of whom also had distant
failure, and 4 patients had distant failure alone.
All local failures were in field. Four patients died
of other causes; 3 were related to toxicity, or possi-
ble toxicity, as detailed above, and 1 patient died of
lung cancer. One patient was lost to follow-up.
Twenty-four patients (52%) remain alive without
evidence of disease (Figures 2 and 3).
DISCUSSION
This study demonstrates that an acceleration of
the HxCRT regimen, enacted by removing the
1-week treatment break from the original proto-
col, is feasible when accompanied by temporary
enteral feeding in most patients. This conclusion
is limited by lack of compliance of many patients
with the original recommendation to have feeding
tubes inserted prior to therapy.
The importance of weight loss as a predictor of
poor outcome has been documented in many can-
cers, including lung, esophageal, and head and
neck cancers.13–15 Weight loss during chemoradia-
tion of head and neck cancer has also been found
to be correlated with cisplatin-related nephrotoxic-
ity.16 The best approach to maintaining weight
and minimizing weight loss during treatment of
HNSCC with RT has been shown in multiple stud-
ies to be PEG placement.9,10,17 PEG appears to be
superior to jejunal feeding tubes.18 However, it is
possible that PEG may increase the risk of stric-
tures compared with nasogastric feeding tubes.18
This issue has been controversial.19
In the current study we have observed a mar-
ginally statistically significant difference in weightFIGURE 1. Locoregional failures.
FIGURE 2. Actuarial overall survival.
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loss during treatment among those patients who
had PEG placed compared to those who did not.
The weight loss in patients with prophylactic PEG
compares favorably to the average 10% weight
loss seen in the Duke randomized trial, in which
only 44% of patients received PEG, only few of
which placed before therapy.1 Our results mirror
the effect of PEG on weight loss reported in a study
of patients treated at the University of Pennsylva-
nia with either chemotherapy and standard fractio-
nation RT or hyperfractionated therapy.8 Two addi-
tional studies by Adelstein et al2,5 also confirm the
importance of PEG placement in the maintenance
of weight during treatment.
An important factor in predicting outcome of
HNSCC is the amount and duration of required
treatment breaks. A number of studies have
shown that radiation treatment breaks of a week
or more are correlated with a poor outcome.20,21
However, these studies were conducted in pa-
tients whose treatment breaks were caused by
acute toxicity, who might have had adverse prog-
nostic features. The effect of a planned treatment
break, as done in the original Brizel study, is not
as clear. While reducing overall treatment time
from 7 to 6 weeks has been found to be beneficial
in randomized studies of radiation alone,4,11 it is
not yet known whether a similar benefit in accel-
erating radiotherapy is gained when concurrent
chemotherapy is added. This issue is being ad-
dressed in current randomized studies such as a
study by the RTOG of accelerated versus standard
fractionated RT, both delivered concurrent with
chemotherapy. The result of this and other similar
studies will help resolve this issue in the near
future. Furthermore, it should be stated that pre-
venting weight loss to eliminate the need for treat-
ment breaks may not result in the same outcome
as in unsupported patients who do not lose weight.
The local/regional tumor control and survival
rates in our study are comparable to the data from
the original HxCRT study of Brizel et al,1 with ap-
proximately 50% long-term survival and 70%
local/regional control rate. However, the patients
in our study, selected due to their ineligibility for
other organ preservation protocols offered at our
institution to those with resectable disease, may
have had more advanced local/regional disease.
Assessing whether or not the elimination of the
planned treatment break has resulted in improved
local/regional control rates compared with the origi-
nal protocol, or compared with other trials, would
require a study of this regimen in unselected
patients with stage III-IV disease.
The main concern in this accelerated regimen
is whether the rate of late complications has been
excessive. The primary late complication in our
study was hypopharyngeal/esophageal strictures
and late dysphagia. Strictures requiring dilation
occurred in 15% of the patients. This is equal to
the stricture rate of 14% reported in a study of
HxCRT regimen identical to the original Duke
protocol, containing a planned treatment break of
5 to 11 days, which was conducted in community
hospitals.7 A stricture rate of 21% was reported
by investigators from the Cleveland Clinic follow-
ing RT concurrent with cisplatin and 5-FU, and
twice-daily RT resulted in a higher rate compared
with once-daily RT.22 In comparison, lower rates
of strictures have been reported following less in-
tensive regimens. Laurell et al23 reported 22 cases
of upper esophageal strictures out of 642 (3.4%)
patients with head and neck cancer treated with
standard fractionated RT alone. In this study, the
lowest dose to the sites of strictures was 60 Gy.
In comparison, lower doses to the hypopharynx
(50 Gy) associated with strictures were found in
the current study and following another regimen of
intensive chemo-RT.23 Thus, concurrent chemo-RT
seems to shift the dose–response curve of this com-
plication to the left. However, it does not seem that
omitting the mid-treatment break has substan-
tially increased this risk compared with the origi-
nal, less accelerated regimen. It should be noted
that a longer follow-up interval may result in addi-
FIGURE 3. Actuarial progression-free survival.
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tional cases of late dysphagia in our series, whose
current median follow-up interval is 2.5 years.
Recent studies of potential strategies to reduce
late dysphagia following intensive chemoradiation
include the use of radiation protectors24 and of
intensity-modulated radiotherapy.25 The clinical
efficacy of these strategies requires validation.
In conclusion, the acceleration of the HxCRT
regimen for patients selected due to having ad-
vanced nonresectable local/regional disease resulted
in tumor control rates similar to those reported for
patients who were not selected according to these
criteria and had received the original HxCRT regi-
men. Comparison of the efficacy of the AccHxCRT
with other intensive regimens requires its evalua-
tion in nonselected patients with stage III-IV tu-
mors. An aggressive policy of weight management
such as prophylactic PEGs is one of the avenues to
facilitate the intensification of chemo- RT. Further
steps are required in order to reduce late dyspha-
gia in patients treated with similar regimens.
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